ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

Abstract

This is an article summarizing the results of the phase I/IIa study ANCHOR, which looked at the possibility of using melflufen in combination with dexamethasone and daratumumab or bortezomib in the treatment of patients with relapsed or refractory multiple myeloma.

Keywords

• Anchor study
• melflufen
• daratumumab
• bortezomib
• treatment
• relapsed
• refractory
• multiple myeloma